Drug-resistant tuberculosis in HIV-infected persons: Italy 1999-2000

Infection

Volumn 32, Issue 6, 2004, Pages 238-332

  Vanacore, P ^a   Koehler, B ^b   Carbonara, S ^c   Zacchini, F ^d   Bassetti, D ^e   Antonucci, G ^b   Ippolito, G ^a   Girardi, E ^a  

^a Ist Naz Malat Infettive L S ^*  (Italy)

^b Clinical Biochemistry Department   (Italy)

^c UNIVERSITY OF BARI   (Italy)

^d MISERICORDIA HOSPITAL   (Italy)

^e UNIVERSITY OF GENOA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ETHAMBUTOL; ISONIAZID; PYRAZINAMIDE; RIFAMPICIN; STREPTOMYCIN; TUBERCULOSTATIC AGENT;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ASSOCIATION; FEMALE; HOSPITAL DEPARTMENT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION RISK; INTERMETHOD COMPARISON; ITALY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIDRUG RESISTANCE; PATIENT SELECTION; PREVALENCE; PROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; STATISTICAL SIGNIFICANCE; TUBERCULOSIS; ANTIBIOTIC RESISTANCE; LUNG TUBERCULOSIS; MIDDLE AGED; PUBLIC HOSPITAL; STATISTICS;

ADULT; AGED; ANTIBIOTICS, ANTITUBERCULAR; ANTITUBERCULAR AGENTS; DRUG RESISTANCE, BACTERIAL; DRUG RESISTANCE, MULTIPLE; FEMALE; HIV INFECTIONS; HOSPITALS, PUBLIC; HUMANS; ISONIAZID; ITALY; MALE; MIDDLE AGED; PREVALENCE; PROSPECTIVE STUDIES; RIFAMPIN; RISK FACTORS; TUBERCULOSIS, PULMONARY;

EID: 16644388084     PISSN: 03008126     EISSN: None     Source Type: Journal    
DOI: 10.1007/s15010-004-3127-8     Document Type: Article

References (19)

1. Dye C, Espinal MA, Watt CJ, Mbiaga C, Williams BG: Worldwide incidence of multidrug-resistant tuberculosis. J Infect Dis 2002; 185: 1197-1202.
2. Pablos-Méndez A, Raviglione MC, Laszlo A, Binkin N, Rieder HL, Bustreo F, Conn DL, Lambregts-van Weezenbeek CS, Kim SJ, Chaulet P, Nunn P: Global surveillance for antituberculosis-drug resistance 1994-1997. N Engl J Med 1998; 338: 1641-1649.
3. Espinal MA, Laszlo A, Simonsen L, Boulahbal F, Kim SJ, Reniero A, Hoffner S, Rieder HL, Binkin N, Dye C, Williams R, Raviglione MC: Global trends in resistance to antituberculosis drugs. N Engl J Med 2001; 344: 1294-1303.
4. Cohn DL, Bustreo F, Raviglione MC: Drug-resistant tuberculosis: review of the worldwide situation and the WHO/IUATLD Global Surveillance Project International Union against Tuberculosis and Lung Disease. Clin Inf Dis 1997; 24 (Suppl. 1):121-130.
5. Decker CF, Lazarus A:Tuberculosis and HIV infection. How to safely treat both disorders concurrently. Postgrad Med 2000; 108: 57-68.
6. Barnes PF: The influence of epidemiologicfactors on drug resistance rates in tuberculosis. Am Rev Resp Dis 1998; 136: 325-328.
7. Gordin FM, Nelson ET, Matts JP, Cohn DL, Ernst J, Senator D, Besch CL, Crane LR, Sampson JH, Bragg PS, El-Sadr W: The impact of human immunodeficiency virus infection in drug-resistant tuberculosis. Am J Respir Crit Care Med 1996; 154: 1478-1483.
8. Pozniak A: Multidrug-resistant tuberculosis and HIV infection. Ann N Y Acad Sci 2001; 953: 192-198.
9. Angarano G, Carbonara S, Costa D, Gori A and the Italian Drug-Resistant Tuberculosis Study Group: Drug-resistant tuberculosis in human immunodeficiency virus infected persons in Italy. Int J Tuberc Lung Dis 1998; 2: 303-311.
10. Salamina G, Sodano L, Mezzetti F, Moro ML: The threat of multid rug-resistant tuberculosis: results of 1 yr of surveillance in the Lombardy region of Italy. Monaldi Arch Chest Dis 1999; 54: 332-336.
11. Girardi E, Antonucci G, Tronci M, Bordi E, Ippolito G: Drug resistance patterns among tuberculosis patients in Rome, 1990-1992. Scan J Inf Dis 1996; 28: 487-491.
12. Migliori GB, Fattorini L, Vaccarino P, Besozzi G, Saltini C, Orefici G, Iona E, Matteelli A, Fiorentini F, Codecasa LR, Casali L, Cassone A, SMIRA (Italian Multicentre Study on Resistance to Anti-tuberculosis drugs) Study Group: Prevalence of resistance to anti-tuberculosis drugs: results of the 1998-1999 national survey in Italy. Int J Tuberc Lung Dis 2002; 6: 32-38.
13. E. Girardi: Outcome of treatment of HIV associated tuberculosis in the era of HAART. XIV International AIDS Conference. Barcelona, Spain 7-12 June 2002. Abstract ThPeB7268.
14. Centers for Disease Control and Prevention: Prevention and treatment of tuberculosis among patients infected with human immunodeficiency virus: principles of therapy and revised recommendations. MMWR 1998; 40 RR-20:5.
15. Loddenkemper R, Sagebiel D, Brendel A: Strategies against multidrug-resistant tuberculosis. Eur Respir J 2002; 36(Suppl.): 665-775.
16. Robert J, Trystram D, Truffot-Pernot C, Carbonnelle B, Grosset J: Surveillance of Mycobacterium tuberculosis drug resistance in France, 1995-1997. AZAY Mycobacteria Study Group. Int J Tuberc Lung Dis 2000; 4: 665-672.
17. Lambregts-van Weezenbeek CS, Jansen HM, Nagelkerke NJ, van Klingeren B, Veen J: Nationwide surveillance of drug-resistant tuberculosis in The Netherlands: rates, risk factors and treatment outcome. Int J Tuberc Lung Dis 1998; 2: 288-295.
18. El Sahly HM, Adams GJ, Soini H, Teeter L, Musser JM, Graviss EA: Epidemiologic differences between United States and foreign-born tuberculosis patients in Houston, Texas. J Infect Dis 2001; 183: 461-468.
19. Schwoebel V, Lambregts-van Weezenbeek CS, Moro ML, Drobniewski F, Hoffner SE, Raviglione MC, Rieder HL: Standardization of antituberculosis drug resistance surveillance in Europe. Recommendations of a World Health Organization (WHO) and International Union Against Tuberculosis and Lung Disease (IUATLD) Working Group. Eur Respir J 2000; 16: 364-371.